Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Fineline Cube Apr 30, 2026
Company Drug

GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma

Fineline Cube Jan 11, 2024

GSK plc (NYSE: GSK) has received approval for a second indication in China for its...

Company Deals

China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions

Fineline Cube Jan 11, 2024

China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has...

Company Deals

WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal

Fineline Cube Jan 11, 2024

WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...

Company Deals

Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement

Fineline Cube Jan 11, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its...

Policy / Regulatory

China’s NHC Unveils Strategy to Enhance Pediatric Healthcare by 2025

Fineline Cube Jan 11, 2024

The National Health Commission (NHC) has issued a set of Opinions aimed at “Promoting the...

Company Deals

Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development

Fineline Cube Jan 11, 2024

Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...

Company Drug

Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China

Fineline Cube Jan 11, 2024

Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...

Company

C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials

Fineline Cube Jan 11, 2024

C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...

Company

Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies

Fineline Cube Jan 11, 2024

Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...

Policy / Regulatory

Corruption Investigations Target Former HSA Officials in Guizhou and Hainan Amid Nationwide Crackdown

Fineline Cube Jan 11, 2024

Corruption investigations have been launched against former senior officials of the Healthcare Security Administration (HSA)...

Company Deals

Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China

Fineline Cube Jan 11, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...

Company Drug

GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia

Fineline Cube Jan 11, 2024

Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...

Company Deals

GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001

Fineline Cube Jan 10, 2024

UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio,...

Company

WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China

Fineline Cube Jan 10, 2024

WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh

Fineline Cube Jan 10, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...

Company Drug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Fineline Cube Jan 10, 2024

Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...

Company Drug

Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration

Fineline Cube Jan 10, 2024

The US Food and Drug Administration (FDA) has accepted for priority review a filing from...

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Fineline Cube Jan 10, 2024

The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...

Company Hospital

Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price

Fineline Cube Jan 10, 2024

China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...

Company Drug Medical Device

AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU

Fineline Cube Jan 10, 2024

AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...

Posts pagination

1 … 410 411 412 … 659

Recent updates

  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
  • HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia
  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Company Medical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.